Thursday, November 19, 2026

JD's Q3 and JD Health's Profit Drop: The Earnings Squeeze in China E-commerce and Online Healthcare

HK 09618HK 06618HK 00241
Why today:As of the 11/18 Hong Kong close, JD.com (09618) fell 7.18% and ranks #1 on the HK heat list with relative volume of 2.1x; JD Health (06618) plunged 15.43% on 5.9x volume and Alibaba Health (00241) fell 5.2% on 2.6x volume. The JD ADR closed down 2.01% and was roughly flat after hours. JD Health's Q3 revenue rose 16.9% to RMB20.02B, but net profit fell 15.3% to RMB1.557B. Alibaba Health reports interim results next week, after several brokers cut their FY2027 forecasts.

The question this piece answers: JD.com's Q3 profit rose year over year and losses at its new businesses narrowed, so why did the JD stocks sell off hard, with JD Health down 15% in a single day? Where exactly is the profit recovery in Chinese e-commerce and online healthcare stuck? Data as of Nov 18, 2026 close (HK market close for HK stocks; ET close for the JD ADR).

Report date: 2026-11-18 (ET) | Data cutoff: HK close and US close on 2026-11-18 | Sources: JD.com and JD Health HKEX filings (2026-11-17), Tencent/East Money quotes and valuation data, yfinance, earnings call transcript (Motley Fool), financial media and public X posts


1. Nov 18 in Hong Kong: the subsidiary out-traded its parent

At the Nov 18 Hong Kong close, JD Health (06618) finished at HK$34.86, down 15.43%. Its intraday low of HK$33.82 was nearly 18% below the prior close. JD Health traded HK$2.143bn that day, more than the HK$1.998bn traded in its parent JD.com (09618). When a HK$111bn subsidiary out-trades its HK$262bn parent, the selling is clearly concentrated in the subsidiary. JD.com fell 7.18% to HK$97.65, and Alibaba Health (00241) fell 5.2% in sympathy. On Aya's HK heat list, JD.com ranked #1 and Alibaba Health #3, and JD Health traded 5.9x its normal volume.

The timing matters. Both reports came out after the HK close on Nov 17: JD Health filed an inside-information notice at 17:00 HKT, and JD.com posted its Q3 results at 17:44 HKT. The JD ADR reacted the same US day (Nov 17), closing down about 7.7%, then slipped another 2.01% on Nov 18 to $24.92. Hong Kong only got its first chance to trade the numbers on Nov 18. Across two sessions the ADR fell 9.51% and the HK line fell 9.67% from its Nov 16 close. The near-identical declines suggest this was a fundamental repricing, not a flow story in one market.

As of writing, the premise of the topic still holds: all three stocks remain near their post-earnings lows, and there was no after-hours bounce in the US.

Around earnings: JD Health fell far more than its parent

The point to take from the chart: in the week before earnings, all three drifted lower together. On Nov 18 JD Health broke away sharply to the downside, and Alibaba Health was dragged down by sector sentiment.

2. JD's Q3: the income statement improved, cash flow got worse

Start with JD.com's Q3. Per the filing, net revenue was RMB309.6bn, up 3.5% YoY. Operating income was RMB5.2bn versus a RMB1.1bn loss a year earlier. Non-GAAP net income attributable to shareholders was RMB8.3bn, up 43.7%. On those numbers alone, this is a profit-recovery report.

The improvement came from two places.

First, core retail held its margin. JD Retail earned RMB15.1bn in operating income, a 5.8% margin versus 5.9% a year ago. On the call, management said retail gross margin has expanded YoY for 18 straight quarters and crossed 20% for the first time (gross margin is the share of revenue left after the cost of goods, a gauge of bargaining power and category mix). Retail revenue grew only 2.9%, though. Electronics and home appliances, the biggest category, brought in RMB127.7bn, down 0.7% against a high base from last year's government trade-in subsidies. Management also acknowledged that higher electronics prices and subsidy-driven demand pull-forward will affect sales timing in the coming quarters. Growth was stronger in general merchandise (+8.1%) and marketplace and advertising revenue (+9.6%).

Second, losses at the new businesses (mainly food delivery, plus Jingxi and international) narrowed sharply. Q3 new-business operating loss was RMB9.64bn versus RMB15.74bn a year ago, RMB6.09bn smaller, a 38.7% improvement. Management said food-delivery losses narrowed more than 50% YoY while orders and users still grew sequentially. The expense line confirms it: marketing spend fell 26.2% from RMB21.1bn to RMB15.5bn, mainly because food-delivery subsidies became more efficient.

The catch is that the YoY comparison looks much better than the sequential one.

JD new-business operating loss: sharply lower YoY, nearly flat QoQ

The chart shows new-business losses of RMB9.85bn in Q2 and RMB9.64bn in Q3 this year, an improvement of only about RMB0.21bn quarter on quarter. Much of the YoY gain reflects how high the base was: Q3 2025 was the peak of the food-delivery war, when spending was heaviest. New-business revenue also fell 49.8% to RMB7.83bn, so each RMB100 of revenue carried roughly RMB123 of operating loss, versus about RMB101 a year earlier. Absolute losses are shrinking, but unit economics (whether each order makes or loses money), measured by loss margin, got worse YoY. Sequentially the loss margin improved from about 135.7% in Q2. My read is that food delivery has moved past the "spend to grab volume" phase into a phase of marginal improvement, and that improvement is clearly slower than the market had hoped. Management's target is to cut food-delivery investment significantly YoY in 2027, without quarterly figures.

What really upset the market was cash flow. Q3 operating cash flow was an outflow of RMB18.7bn. Free cash flow (operating cash flow minus capex, the cash the company can actually deploy) was negative RMB23.9bn, versus negative RMB11.2bn a year earlier. Inventory rose about RMB20.7bn from the start of the year, and inventory days climbed from 35.8 to 41.2. Management pointed to trailing-twelve-month FCF of RMB18.8bn, but that figure was RMB31.4bn a quarter earlier, a drop of roughly RMB12.6bn in one quarter. One explanation is seasonal working capital: stocking up for Singles' Day and new iPhones. The other is slower inventory sell-through after subsidies pulled electronics demand forward. There isn't enough data yet to say which dominates; Q4 inventory and payables will tell.

Against expectations: the consensus figures cited on X vary somewhat. @Manhattan_Betsy cited expectations of roughly RMB311.5bn in revenue and RMB8.59bn in adjusted net income; @CHItrader cited adjusted EPS per ADS of $0.88 versus $0.93 expected. On those measures, JD slightly missed on both revenue and adjusted profit. On the other side, @Nathan_Wilrj noted Bernstein ($38 target), Mizuho ($34) and Barclays ($33) all reiterated positive ratings after the print. In short, JD.com delivered profit improvement in the right direction but slightly below expectations, with clearly worse cash flow. Those three things explain a drop of around 7%.

3. JD Health: why didn't higher revenue mean higher profit?

JD Health fell twice as much as its parent, and the reason only shows up when you take its income statement apart layer by layer. The filing was a one-page inside-information notice with just five headline numbers and no expense breakdown. The analysis below uses only those disclosed numbers, and any inference is labeled as such.

Metric (quarter, RMB 100m)Q3 2026Q3 2025YoY
Revenue200.17171.20+16.9%
Non-IFRS operating profit15.7513.78+14.3%
Non-IFRS net profit19.3119.02+1.5%
Operating profit (IFRS)11.9512.43-3.9%
Profit for the period (IFRS)15.5718.39-15.3%

JD Health Q3: the further down the P&L, the worse the growth

The chart shows how profit got eaten away between revenue (+16.9%) and net profit (−15.3%). It happened in three places:

Layer 1: the operating margin slipped, but only a little. Non-IFRS operating profit grew 14.3%, slightly slower than revenue's 16.9%. Per an analyst estimate cited by Sohu, adjusted operating margin fell about 0.2 points to 7.9%. Investing.com attributed this to higher selling and marketing spend. The filing itself doesn't break out expenses, so treat that attribution as medium confidence. By size, this layer explains only a small part of the profit decline.

Layer 2: non-cash adjustments jumped. The gap between non-IFRS and IFRS net profit was about RMB374m in Q3 versus about RMB64m a year earlier. That RMB310m increase roughly matches the RMB281m absolute decline in reported net profit. In other words, most of the 15.3% drop in reported profit came from these adjustments. Such items typically include share-based compensation, amortization of intangibles and fair-value changes on investments, but the filing doesn't itemize them, so I can't confirm which one drove it. To be clear: I was unable to verify the source of this gap.

Layer 3: interest and other non-operating income fell. On an IFRS basis, net profit minus operating profit (mainly interest income and similar items, after income tax) fell from about RMB595m to about RMB362m. Media reports cited lower interest income as rates declined. JD Health holds a lot of cash, so rate cuts hit it more directly than a typical retailer. This layer explains why non-IFRS net profit grew just 1.5%: almost all the extra operating profit was offset by lower interest income.

So the accurate description of "revenue up, profit down" is this: operating margins were broadly stable (a small decline), and the drop in reported profit came mainly from non-cash adjustments and lower interest income. If you only looked at Layer 3, this would not be a severe decline.

So why a 15% drop? I think it reflects a break in expectations rather than how bad this one quarter was. East Money data show JD Health's H1 2026 net profit grew 32.4% YoY. The market had been valuing it on the premise that profit grows faster than revenue. In Q3, reported profit swung to a YoY decline and adjusted net profit growth slowed to 1.5%, a very large gap. The Q4 outlook mattered even more: per Sohu, CLSA expects Q4 revenue growth to slow to about 11% because a milder flu season may slow drug sales and weak consumption may weigh on health supplements. CLSA still rates the stock Outperform, and BofA reiterated Buy with a HK$57 target, so analysts disagree.

The topic brief also mentioned online pharmacy regulation. This round of research found no new regulatory document or policy that maps directly to this sell-off, so this piece does not treat regulation as a cause, and that section is kept short.

Over a longer window, JD Health's 9-month revenue was about RMB60.9bn (+16.2%) and net profit about RMB4.99bn (+12.6%), adding H1 and Q3 figures (method in the appendix). Full-year growth is still double digits; the pace has just shifted from accelerating to decelerating.

4. Alibaba Health: a stress test of the same logic

Alibaba Health had no earnings of its own, yet it fell 5.2% on 2.6x relative volume because investors applied JD Health's problem to it. Its downgrade cycle actually started earlier. In September 2026, UBS cut its FY2027 revenue growth forecast from 10–15% to 7–10%, lowered its adjusted EPS estimate to RMB0.13, and cut its target to HK$2.8 with a Sell rating, citing slower growth in health supplements and medical devices and fewer price discounts. BofA cut its target 17.6% to HK$4.2 but kept Buy; Morningstar lowered its fair value to HK$4 and said it preferred JD Health.

At HK$2.735, Alibaba Health now trades below UBS's HK$2.8 target. The company says its board meets on Nov 24 to approve results for the six months to Sept 30, 2026. That will be the next test of whether online healthcare margins can hold.

5. What the market is betting on

The three stocks' valuations side by side:

StockNov 18 closeDay changeP/E (TTM, Tencent)~2–3yr P/E-TTM percentile (self-calc, approx.)
JD.com 09618HK$97.65-7.18%12.08xDistorted, not used (see appendix)
JD Health 06618HK$34.86-15.43%18.69x~1% (near range low)
Alibaba Health 00241HK$2.735-5.2%20.17x~0% (range low)

P/E is share price divided by earnings per share, roughly how many years of current earnings it takes to earn back the price. The percentile shows where today's valuation sits in its recent history; 1% means the stock was more expensive 99% of the time over that period.

For JD Health, East Money's self-calculated median P/E-TTM over roughly three years is about 33.75x, versus about 18x now, almost at the bottom of the range. That valuation implies the market no longer treats it as an online-healthcare platform growing profit at 30%, but as something closer to an online pharmacy with mid-teens revenue growth and limited room to expand margins. Whether that's right depends on whether the pressure in Layers 2 and 3 persists. Lower interest income from falling rates is hard to reverse in the short term. The operating margin slipped only slightly, but if Q4 revenue growth really slows to about 11% and marketing spend doesn't come down, operating leverage (profit growing faster than revenue) disappears, and the low multiple is justified. Conversely, if the operating margin recovers, today's valuation reflects excessive pessimism. The evidence so far rules out neither scenario.

For JD.com, a P/E around 12x wasn't high to begin with. The market is betting on something else: whether new-business losses fall meaningfully in 2027, and whether negative free cash flow is a one-off. With new-business losses down only about RMB0.2bn from Q2 to Q3, the market can't price in losses quickly going to zero. JD also closed its EUR1.335bn purchase of a 59.8% stake in Germany's CECONOMY (parent of MediaMarkt) this quarter, so overseas spending becomes a new variable for profit and cash flow over the next few quarters.

6. What to watch next

  • Nov 24: Alibaba Health interim results. Watch adjusted net profit growth and whether supplements and medical devices keep slowing. If its margin holds, JD Health's problem looks more company-specific; if it also slips, the case for a sector-wide de-rating gets stronger.
  • JD Q4 results (early March 2027 based on past years; confirm with company notice). Three numbers matter most. First, whether new-business losses come in clearly below Q3's RMB9.6bn; if they stay above RMB9bn, the "significant 2027 loss reduction" story weakens. Second, whether inventory falls after peak season and inventory days get back under 40, which would show whether the Q3 cash-flow deterioration was seasonal or structural. Third, whether electronics and appliances return to growth against the high subsidy base.
  • JD Health full-year results (expected March 2027). Check whether Q4 revenue growth slows to about 11% as CLSA expects, and whether the gap between reported and adjusted profit keeps widening. If the company itemizes the adjustments, that will show whether the Layer 2 pressure is one-off or ongoing.
  • Trade-in subsidy policy. Whether 2027 subsidies continue, and at what scale, directly affects whether JD's electronics and appliances revenue can recover.

7. Conclusion

JD's Q3 profit improvement is real: core retail margin held around 5.8%, and new businesses lost RMB6.1bn less than a year ago. But much of the YoY gain comes from the high base of last year's food-delivery war; sequential loss reduction has nearly stalled, and the quarter burned RMB23.9bn of free cash flow, which is what the market cares about most. JD Health saw reported profit fall while operating profit came under only mild pressure; the drop in reported net profit came mainly from non-cash adjustments and lower interest income. Its 15% plunge reflects the gap in expectations as growth shifted from accelerating to decelerating, plus a weaker Q4 outlook, which pushed the valuation to the bottom of its recent range. The profit recovery in Chinese e-commerce and online healthcare is still underway but slower than the market had assumed; next come Alibaba Health's interim results on Nov 24 and JD's Q4 loss-reduction and inventory data.


Appendix: Data and Sources

A1. JD.com Q3 2026 key financials (RMB 100m; converted from RMB millions)

MetricQ3 2026Q3 2025YoY/Change
Net revenue3,095.932,990.59+3.5%
JD Retail revenue2,579.662,505.77+2.9%
JD Logistics revenue639.53550.84+16.1%
New businesses revenue78.31155.92-49.8%
Electronics & home appliances1,277.251,285.87-0.7%
General merchandise1,054.50975.05+8.1%
Marketplace & marketing281.42256.88+9.6%
Gross margin (calc.)18.08%16.88%+1.2pt
Fulfillment236.40220.02+7.4%
Marketing155.34210.50-26.2%
R&D77.3056.46+36.9%
JD Retail op. income (margin)150.68 (5.8%)148.28 (5.9%)+1.6%
JD Logistics op. income (margin)19.21 (3.0%)12.82 (2.3%)—
New businesses op. loss (margin)-96.42 (-123.1%)-157.36 (-100.9%)38.7% narrower
Operating income (GAAP)51.54-10.51Turned positive
Non-GAAP operating income73.472.11—
Net income attrib.65.0352.76+23.3%
Non-GAAP net income attrib.83.2757.96+43.7%
Operating cash flow-187.08-80.35—
Free cash flow-238.61-112.49—
Inventory (period-end vs YE2025)1,161.66954.28+207.38
Inventory days (TTM)41.235.8—
TTM free cash flow188 (314 at Q2)126—

A2. Calculations (all checked with verify_calc)

Derived valueFormulaResult
JD Q3'26 gross margin(3,095.93−2,536.32)/3,095.9318.08%
JD Q3'25 gross margin(2,990.59−2,485.85)/2,990.5916.88%
New-business loss reduction(96.42−157.36)/157.36−38.7%
New-business loss QoQ change98.5−96.42~RMB0.21bn
New-business loss margin Q3/Q296.42/78.31; 98.5/72.6123.1%; 135.7%
JD Retail op. income YoY(150.68−148.28)/148.28+1.6%
JD Health operating margin11.95/200.17; 12.43/171.205.97%; 7.26%
JD Health adj. net margin19.31/200.17; 19.02/171.209.65%; 11.11%
Adj. minus reported net profit19.31−15.57; 19.02−18.393.74; 0.64 (RMB 100m)
Net profit minus op. profit15.57−11.95; 18.39−12.433.62; 5.95 (RMB 100m)
JD Health 9M net profit34.37 (H1)+15.57 (Q3) vs 25.96+18.3949.94, +12.6%
JD Health 9M revenue408.88+200.17 vs 352.90+171.20609.05, +16.2%
JD ADR two-day drop24.92/27.54−1−9.51%
JD HK two-day drop97.65/108.10−1−9.67%
JD Health intraday max drop33.82/41.22−1−17.95%
JD Health vs Nov 1034.86/42.84−1−18.63%

Note: East Money labels JD Health's financials as HKD, but JD Health reports in RMB; after checking the 2025 interim revenue (RMB35.29bn), the figures are treated as RMB. JD.com's self-calculated P/E-TTM percentile (~81%, 17.95x) differs sharply from the Tencent quote P/E (12.08x) because of the filing-lag assumption and big 2025 earnings swings during the food-delivery spending phase, so the body text does not use it.

A3. Timeline

DateEvent
Sep 21–22, 2026UBS cuts Alibaba Health target to HK$2.8 (Sell); BofA to HK$4.2 (Buy); Morningstar cuts fair value to HK$4
Nov 12, 2026Alibaba Health announces Nov 24 board meeting for interim results; JD completes 59.8% CECONOMY acquisition
Nov 17, 2026, 17:00 HKTJD Health files Q3 unaudited inside information
Nov 17, 2026, 17:44 HKTJD.com posts Q3 2026 results; ADR closes down ~7.7% at $25.43 that US day
Nov 18, 2026HK: JD -7.18%, JD Health -15.43%, Alibaba Health -5.2%; ADR -2.01% to $24.92
Nov 24, 2026Alibaba Health interim results board meeting

A4. Aya heat data (Nov 18, 2026 close)

StockHK heat rankHeatChangeRelative volumeDrivers
JD.com 09618173-7.1%2.1xVolume spike, sharp drop, just reported
Alibaba Health 00241369-5.2%2.6xVolume spike, sharp drop
JD Health 066181254-15%5.9xVolume spike, sharp drop

Also: on the US heat list, Alibaba (BABA) ranked #8 (-2.5%); JD was not in the US top 20.

A5. Market commentary excerpts

  • @RossDongRD (X, Nov 18): JD net profit +44% YoY but free cash flow of −RMB23.9bn shows "the market doubts cash-flow quality."
  • @CHItrader (X, Nov 17): adjusted EPS $0.88 vs $0.93 est.; revenue $46.18bn vs $46.33bn est.; "FCF -RMB23.86B."
  • @Manhattan_Betsy (X, Nov 17): revenue est. ~RMB311.5bn; adjusted net income est. ~RMB8.59bn.
  • @Nathan_Wilrj (X, Nov 18): Bernstein ($38), Mizuho ($34), Barclays ($33) reiterated positive ratings.
  • @AlphaQuantMoney (X, Nov 18): JD Health non-IFRS operating margin 7.86%; argues the drop did not change operating growth.
  • CLSA (via Sohu, Nov 18): JD Health Q4 revenue growth may slow to ~11% on a mild flu season and weak supplement demand; Outperform maintained.
  • BofA (same source): reiterates Buy on JD Health, HK$57 target.
  • UBS (via 10jqka, Sep 21): Alibaba Health FY2027 revenue growth cut to 7–10%; HK$2.8 target; Sell.

A6. Source list

  1. JD.com Q3 2026 results announcement, HKEX, 2026-11-17: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1117/2026111700792_c.pdf
  2. JD Health inside information – Q3 2026 unaudited update, HKEX, 2026-11-17: https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1117/2026111700529_c.pdf
  3. JD.com Q3 2026 Earnings Call Transcript, Motley Fool, 2026-11-17: https://www.fool.com/earnings/call-transcripts/2026/11/17/jdcom-jd-q3-2026-earnings-call-transcript/
  4. 10jqka: JD Q3 new businesses lost RMB6.1bn less, 2026-11-18: http://news.10jqka.com.cn/20261118/c681971935.shtml
  5. Sohu: JD Health Q3 profit down 15%, CLSA lowers Q4 revenue expectation, 2026-11-18: https://www.sohu.com/a/1103355091_121885030
  6. Wallstreetcn: JD Q2 2026 results coverage, Aug 2026: https://wallstreetcn.com/articles/3779374
  7. 10jqka: UBS cuts Alibaba Health target to HK$2.8, 2026-09-21: https://stock.10jqka.com.cn/20260921/c680120235.shtml
  8. Caiwen: Alibaba Health board meeting on Nov 24, 2026, published 2026-11-12 (WebSearch result)
  9. Investing.com: Why JD Health shares fell today, 2026-11-18 (WebSearch result)
  10. Tencent quotes/daily bars, East Money valuation and financial indicators (eastmoney.quote / kline / valuation / financials), 2026-11-18
  11. yfinance analyst price target summary (6618.HK / 0241.HK / 9618.HK), 2026-11-18 (may not yet reflect post-earnings revisions; not used in body text)
  12. X posts (via grok-x x_search), Nov 16–18, 2026

For information and research discussion only. Not investment advice.

<!-- AYA_PODCAST -->

🎙️ Podcast script (Chinese, ~20 min, 泓观阳略): read it here

AI-generated by Aya Research from public data and disclosures, for information and research purposes only. Not investment advice.